Board summary
Key figures
77,884
Registered population
63.9% aged 18–64
14.1%
Aged 65+
ICB 14.9% · England 17.9%
53.1%
In IMD quintile 1
ICB 40.7% · England 21.0%
~38,813
Core20 residents (est.)
Resident basis; registered basis ~42,037 · see page 3
10,901
Hypertension register
+8.63% in 3 yrs · England +5.60%
1,022
SMI register
27.6% of Salford (LAD)'s
2,384
COPD register
Reviews +16.77% in 3 yrs
Forecast to 2030
12,822
Hypertension patients, 2030
+1,921 on today
73.5%
QRISK ≥20% on statins, 2030
+2.67pp over 3 yrs
3.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Breast screening remains below national and local averages.
Breast screening is 57.6% (Salford 64.9%, ICB 68.8%, England 69.9%) despite +30.1% growth over 2023 to 2024, which may reflect unverified uptake barriers.
Age-five booster and second MMR doses fall short.
Age-5 4-in-1 coverage is 83.3% (11.7 pp below the 95.0% target) and MMR drops 7.3 pp from 93.1% to 85.8% in Q1 2025/26.
Strong cardiometabolic control despite slower preventive trend growth.
Hypertension control reaches 80.1% (England 70.3%) and non-frail diabetes control 65.1% (England 57.4%), though QRISK ≥ 20% lipid growth (+4.1%) trails England (+6.2%).
Population, age and ethnicity
A younger population with 14.1% aged 65+ sits alongside 961 care home beds
Across 77,884 registered patients, the PCN has a younger demographic profile than England. Patients aged 65 and over form 14.1% of the list (10,974 patients), trailing Salford (14.4%), NHS Greater Manchester ICB (14.9%) and England (17.9%). Children aged 0-17 make up 22.0% (17,159 patients), above Salford (21.4%), ICB (21.8%) and England (19.6%). Census ethnicity shows Gypsy or Irish Traveller residents at 0.1% (Salford 0.1%, ICB 0.1%, England 0.1%) and Roma at 0.1% (Salford 0.2%, ICB 0.1%, England 0.2%). Registered lists represent practice counts, whereas ethnicity figures reflect resident Census estimates.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Salford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Salford LA) | 2,980 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 90.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 65.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Salford LA) | 1,510 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Salford LA) | 15.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients form 53.1% of the list, spanning 55.6 pp between practices
Core20 patients make up 53.1% of the registered list, above Salford (44.0%), the ICB (40.7%) and England (21.0%), though weighted practice shares (54.0%) and resident estimates (38,813) differ. Concentration spans 55.6 pp, from 24.4% at 1/monton Medical Practice to 80.1% at Salford Primary Care Together. Salford Primary Care Together also holds the largest volume with 14,944 estimated Core20 patients. Outreach and clinical capacity could focus on high-deprivation practices where the bulk of Core20 patients reside.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,022
SMI register
1.28% recorded prevalence
430
Learning disability register
0.54% recorded prevalence
24
Care homes, 961 beds
In the PCN catchment
9.2%
Provide unpaid care
Salford (LAD), Census 2021
Severe mental illness prevalence is 1.3% (1,022 patients), above Salford (1.1%), ICB (1.1%) and England (1.0%), while learning disability prevalence is 0.5% (430 patients; Salford 0.5%, ICB 0.6%, England 0.6%). The PCN catchment includes 961 care home beds. Borough rough sleeping (41 people in Salford) cannot be extrapolated to practice lists. The SMI register is above England, so physical-health checks for this group are the larger workload to protect.
Severe mental illness: physical health checks
SMI prevalence is 1.3% (England 1.0%). Recorded checks reached 85.3% for blood pressure (England 83.4%) and 85.1% for BMI (England 82.1%). Smoking cessation offers fell 1.2 pp over 2023 to 2025 (England +0.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,901
Hypertension register
+8.63%
Register growth, 3 yrs
Salford (LAD) +5.45% · England +5.60%
+4.91pp
BP control, under 80
≤140/90 · +2.58pp aged 80+
+1,921
More patients by 2030
Forecast 12,822 (16.15%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.7% (10,901 patients across a registered list of 77,884), above Salford (LAD) (12.4%) but below England (15.2%) and NHS Greater Manchester Integrated Care Board (14.4%), with 3-year register growth of +8.6% (2023 to 2025; England +5.6%). Patients treated to target reached 80.1% (England 70.3%, Salford (LAD) 77.6%, ICB 71.4%). Recent blood pressure readings reached 93.8% (England 90.0%), while 3-year recording growth (+3.1% over 2023 to 2025) trails England (+3.6%). High control rates provide a solid foundation to review recall systems so recent recording gains keep pace with national trends.
Lipids and statins
For QRISK ≥ 20%, lipid-lowering therapy is 67.9% (England 63.6%), but 3-year growth of +4.1% (2023 to 2025) trails England (+6.2%). Statin treatment for diabetes without CVD is 77.0% (England 73.2%), trailing 3-year national growth (+1.7% vs +2.1%). Recall audits may help address trailing preventive uptake.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 174,140 | £1.60 | £1.94 | £1.86 | £278,624 |
| Cardiovascular (all), 2025 | 228,660 | £2.42 | £3.15 | £3.33 | £553,357 |
For lipid-regulating drugs in 2026, the PCN prescribed 174,140 items at £1.60 per item (Salford (LAD) £1.54, England £1.86, NHS Greater Manchester Integrated Care Board £1.94). The PCN spends £45,276 less than at England's unit cost across 174,140 items. Unit costs indicate expenditure rather than clinical efficiency.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+19.31%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+6.77%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 3.0% (Salford (LAD) 2.5%, ICB 2.3%, England 1.9%), up +9.9% over 2023 to 2025 (England +2.6%), with 82.8% reviewed (England 76.4%). Asthma prevalence is 6.9% (England 6.6%), and prescribing is 2,028 items per 1000 aged 5-19 (England 1,488). Annual asthma reviews reached 76.2% (England 65.7%), leaving an estimated scale indicator of 1,215 patients without a recorded review across the 5,116 register. Reviewing recall registers can help target unreviewed asthma patients.
Cancer register and children's immunisation
Cancer prevalence is 3.1% (England 3.8%). In Q1 2025/26 childhood COVER data, complete 6-in-1 coverage at 24 months reached 96.1% (target 95.0%). At age 5, MMR dose 1 is 93.1% while dose 2 is 85.8% (a 7.3 pp dose difference; 9.2 pp below the 95.0% target), and the 4-in-1 pre-school booster is 83.3% (11.7 pp below the 95.0% target). Pre-school booster drop-off indicates a need for proactive recall before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of known-stage cancers (6,491 of 11,679) were diagnosed at stage 1 or 2 in NHS Greater Manchester ICB (England 55.3%), with known stage in 70.8% of 16,492 registrations (England 67.0%). This is 19.4 pp below the 75.0% 2028 ambition, requiring about 2,270 extra early cases annually across the ICB, despite a 3.1 pp rise since 2013. PCN breast screening is 57.6% (Salford 64.9%, England 69.9%; +30.1% over 2023 to 2024), at 47.5% at 3/springfield House Medical Practice, 50.2% at Salford Primary Care Together, and 56.0% at St Andrews Medical Centre. Screening shortfalls may delay early detection, warranting targeted practice recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Manchester University NHS Foundation Trust achieved 72.8% against the 85.0% 62-day cancer referral to treatment standard, trailing the target by 12.2 pp while exceeding England (71.2%) and Bolton NHS Foundation Trust (69.7%), but behind NHS Greater Manchester Integrated Care Board (75.7%) and Northern Care Alliance NHS Foundation Trust (78.6%). On the 28-day faster diagnosis standard, Manchester University NHS Foundation Trust reached 80.1%, surpassing the 75.0% standard by 5.1 pp, above England (79.3%) and the ICB (79.5%). Treatment pathway delays beyond diagnosis highlight the need for close primary-secondary care tracking.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Bolton | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 80.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 96.50 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 69.66 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Bolton | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 2.05 | 21.40 |
| CT | 14.66 | 4.10 | 19.40 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 3.48 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 1.33 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 2.06 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 15.78 | 23.14 |
| Community services activity | Salford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 37,955 | 573,310 |
| Referrals | 3,340 | 94,470 |
| Patients with a contact | 15,440 | 183,535 |
Community services (residents of Salford), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 53.9% of all community service contacts among Salford residents (20,470 of 37,955 contacts). High older-adult contact volume across community pathways underscores the importance of coordinating community services with primary care cancer monitoring.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| St Andrews | 108 | 48.6 | 82.6% | 83.3% | 92.2% |
| Chapel Group | 91 | 40.2 | 88.0% | 71.1% | 89.5% |
| (irlam) Salford | 108 | 42.8 | 93.2% | 76.2% | 88.5% |
| 3/springfield | 119 | 66.9 | 66.4% | 76.9% | 83.7% |
| Mosslands Medical | 105 | 42.4 | 51.2% | 57.0% | 75.6% |
| Salford Primary | 126 | 80.1 | 57.8% | 81.9% | 73.6% |
| 1/monton Medical | 96 | 24.4 | 49.5% | 71.2% | 71.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Four preventive measures trail England's three-year growth despite rapid chronic disease register expansion
Four clinical measures trail England over 2023 to 2025: QRISK ≥ 20% lipid therapy grew +4.1% (England +6.2%), smoking cessation offers fell 1.2 pp (England +0.1 pp), diabetes statins without CVD grew +1.7% (England +2.1%), and recent hypertension blood pressure recording grew +3.1% (England +3.6%). Conversely, three-year gains lead England in asthma reviews (+19.3% vs +4.4%), heart failure reviews (+13.5% vs +8.7%), and depression register growth (+23.2% vs +7.7%). Slower preventive growth could reflect recall capacity, testable via audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
QRISK statin treatment
Smoking support (SMI)
Diabetes statin (no CVD)
Hypertension BP reading
Breast screening (53-70)
Alcohol record (psychosis)
Asthma reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Salford (LAD) | Asset | PCN | Salford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 24 (961 beds) | n/a | Schools (catchment) | 114 | n/a |
| Children's centres | 6 | 16 | Places of worship | 55 | 118 |
| Libraries | 8 | 16 | Primary schools (LA maintained) | 26 | 52 |
| Primary academies | 12 | 21 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Annual asthma reviews reached 76.2% (England 65.7%) across the 5,116 register, leaving a scale indicator of 1,215 unreviewed patients. For discussion: the PCN could run structured recall using a single review template and flexible after-school or holiday slots in high-Core20 practices. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school booster and MMR2 recall
In Q1 2025/26 (cohort 233), age-5 4-in-1 coverage is 83.3% (11.7 pp below 95.0%) and MMR2 is 85.8% (9.2 pp below 95.0%; 7.3 pp below MMR1 at 93.1%). For discussion: practices could audit age-5 registration lists for unrecorded second MMR and 4-in-1 booster doses and offer flexible catch-up clinic times. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 3
Preventive CVD and smoking recall
Over 2023 to 2025, 4 measures trail England: QRISK >= 20% lipid therapy (+4.1% vs +6.2%), smoking cessation offers (-1.2 pp vs +0.1 pp), diabetes statins (+1.7% vs +2.1%), and recent BP recording (+3.1% vs +3.6%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult case finding review (p2) | Registered population · Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 proactive outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation prompt audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall (p7) | Breast screening coverage: aged 53 to 70 years old | — | PCN |
| Practice phone access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN |
| Option 2 · Pre-school booster and MMR2 recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity test | PCN |
| Option 3 · Preventive CVD and smoking recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
